Nutrition and Cardiovascular Disease: Homocysteine

Abstract

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111–28. 2. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976;57:1079–82. 3. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In Francis RBL, editor. Atherosclerotic cardiovascular disease hemostasis and endothelial function. New York: Marcel Dekker; 1992, p. 183–236. 4. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049–57. 5. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72:315–23. 6. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324–32. 7. Brattstrom L, Israelsson B, Lindgarde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine beta-synthase deficiency. Metabolism 1988;37:175–8. 8. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98:2520–6. 9. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677CT polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288: 2023–31. 11. Selhub J . The Many Facets of Hyperhomocysteinemia: Studies from the Framingham Cohorts J. Nutr 2006;136: 1726S–30S. 12. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005;365: 224–32. 13. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a metaanalysis. JAMA 2002;288:2015–22. 14. Lentz SR, Sobey CG, Piegors DJ, et al Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996;98:24–9. 16. Stamler S, Osborne JA, Jaraki M, et al. Adverse vascular effects of homocysteine are modulated by endotheliumderived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308–18. 17. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370–6. 19. Di Minno G, Davi G, Margaglione M, et al. Abnormalty high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin invest 1993;92: 1400–6. 20. Davi G, Di Minno G, Coppola A, et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001;104:1124–8. 21. Coppola A, D’Angelo A, Fermo I, et al. Reduced in vivo oxidative stress following 5-methyl-tetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. Br J Haematol 2005;131:100–8.